Category: Steris Corp.
An EPA advisory panel meeting that began today could disrupt medical device supply chains if the panel upholds the agency's classification of a ubiquitous sterilizer as carcinogenic.
A scientific advisory panel to the EPA is convening today to evalute the environmental watchdog's determination that a common medical device sterilizer, ethylene oxide, is carcinogenic.
If the panel confirms that assessment, medtech companies warn, it could disrupt the supply chain for their lifesaving products.
Sterigenics is put on the auction block by its private equity owners, who hope the contract sterilization company will fetch $1.5 billion.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic announces leadership roster for post-Covidien merger; Allergan raises outlook; says Valeant offer undervalues company; EuroZone anti-trust regulators to rule next month on $43B Covidien buy; Steris to buy UK's Synergy Health, tax savings eyed; Bioventus bolsters bone healing lineup
Steris agrees to a $1.9 billion buyout of U.K. sterilization services provider Synergy Health in the 1st inversion deal since a U.S. Treasury crackdown.
Here's a look at some of the top legal news stories for medical device companies this week: Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Medtronic fights tax dodging rhetoric in Covidien merger; Travelers holds out on BD's $67M coverage claim; Abbott CEO defends inversions amid corporate exodus furor; Steris, Medtrica win legal fees in Cygnus Medical patent spat;
A federal judge agrees to award legal fees to Steris and Medtrica in their patent infringement win over Cygnus Medical, after a U.S. Supreme court decision reboots the rules on awarding legal costs.
FDA inspectors identify a handful of violations at Steris Isomedix's sterilization facility, including concerns that the company failed to respond appropriately to incidents in which employees were manipulating data.
Steris's (NYSE:STE) Isomedix division is in the FDA's hotseat after inspectors turned up incidents in which employees faked data on testing for medical devices.